Barclays
GOSS icon

Barclays’s Gossamer Bio GOSS Stock Holding History

Barclays’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Buy
7,832,522
+4,766,716
+155% +$1.33M ﹤0.01% 2647
2026
Q1 		$1.01M Buy
3,065,806
+2,489,273
+432% +$3.91M ﹤0.01% 2760
2025
Q4 		$1.79M Buy
576,533
+304,827
+112% +$870K ﹤0.01% 3016
2025
Q3 		$715K Sell
271,706
-67,086
-20% -$148K ﹤0.01% 3583
2025
Q2 		$417K Buy
338,792
+93,692
+38% +$102K ﹤0.01% 3861
2025
Q1 		$270K Buy
245,100
+245,000
+245,000% +$283K ﹤0.01% 3888
2024
Q4 		$90 Sell
100
-20,964
-100% -$18K ﹤0.01% 5185
2024
Q3 		$20.8K Sell
21,064
-748,564
-97% -$720K ﹤0.01% 4894
2024
Q2 		$693K Buy
769,628
+769,528
+769,528% +$576K ﹤0.01% 2819
2024
Q1 		$118 Hold
100
– – ﹤0.01% 4995
2023
Q4 		$91 Sell
100
-100
-50% -$74 ﹤0.01% 5171
2023
Q3 		$166 Buy
200
+99
+98% +$114 ﹤0.01% 4533
2023
Q2 		$121 Sell
101
-41,479
-100% -$51.7K ﹤0.01% 4437
2023
Q1 		$52.4K Sell
41,580
-1,391,040
-97% -$2.66M ﹤0.01% 4433
2022
Q4 		$3.11M Buy
1,432,620
+1,279,971
+839% +$10.5M ﹤0.01% 1957
2022
Q3 		$1.83M Buy
152,649
+147,670
+2,966% +$1.83M ﹤0.01% 1810
2022
Q2 		$41K Buy
+4,979
New +$38.6K ﹤0.01% 4110
2022
Q1 		– Sell
-72,450
Closed -$819K – 5213
2021
Q4 		$819K Buy
+72,450
New +$861K ﹤0.01% 2950
2021
Q3 		– Sell
-13,429
Closed -$109K – 4845
2021
Q2 		$109K Buy
13,429
+12,942
+2,657% +$112K ﹤0.01% 3813
2021
Q1 		$5K Sell
487
-27,234
-98% -$275K ﹤0.01% 4482
2020
Q4 		$268K Buy
+27,721
New +$273K ﹤0.01% 3598
2020
Q3 		– Sell
-52,714
Closed -$685K – 5335
2020
Q2 		$685K Buy
52,714
+51,745
+5,340% +$651K ﹤0.01% 3073
2020
Q1 		$10K Buy
969
+960
+10,667% +$12.5K ﹤0.01% 5814
2019
Q4 		$0 Sell
9
-86,188
-100% -$1.74M ﹤0.01% 6517
2019
Q3 		$1.45M Buy
+86,197
New +$1.71M ﹤0.01% 3268
2019
Q2 		– Sell
-3,138
Closed -$68K – 7050
2019
Q1 		$68K Buy
+3,138
New +$65.4K ﹤0.01% 5663

Other funds holding GOSS

D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.3B AUM 12.57% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM

Barclays's GOSS Position: Q2 2026 in Review

Barclays increased its Gossamer Bio (GOSS) stake by 155% in Q2 2026, buying an estimated $1.33M and bringing the position to 7,832,522 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2647.

Barclays first reported a position in GOSS in Q1 2019 and has held it in 26 quarters since. The position peaked at $3.11M in Q4 2022. 170 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

  • Barclays held 7,832,522 shares of Gossamer Bio worth $1.29M as of Q2 2026.
  • Barclays bought 4,766,716 Gossamer Bio shares in Q2 2026, an estimated $1.33M.
  • Gossamer Bio made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2647 holding.
  • Barclays first reported a position in Gossamer Bio in Q1 2019 and has held it in 26 quarters since.
  • Barclays's Gossamer Bio position peaked at $3.11M in Q4 2022.
  • 170 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.